The efficacy for unresectable hepatocellular carcinoma may be improved by transcatheter arterial chemoembolization in combination with a traditional Chinese herbal medicine formula

Cancer ◽  
2009 ◽  
Vol 115 (22) ◽  
pp. 5132-5138 ◽  
Author(s):  
Yang Yu ◽  
Qingbo Lang ◽  
Zhe Chen ◽  
Bai Li ◽  
Chaoqin Yu ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Herbal Medicine ◽  
Chinese Herbal Medicine ◽  
Transcatheter Arterial Chemoembolization ◽  
Traditional Chinese Herbal Medicine ◽  
Chinese Herbal ◽  
Unresectable Hepatocellular Carcinoma ◽  
Chinese Herbal Medicine Formula ◽  
Arterial Chemoembolization

scholarly journals Jiedu Granule Combined with Transcatheter Arterial Chemoembolization and Gamma Knife Radiosurgery in Treating Hepatocellular Carcinoma with Portal Vein Tumor Thrombus

2019 ◽  
Vol 2019 ◽  
pp. 1-8
Author(s):  
Jianchu Wang ◽  
Jinhong Luo ◽  
Xiaolan Yin ◽  
Wei Huang ◽  
Huangming Cao ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Herbal Medicine ◽  
Portal Vein ◽  
Chinese Herbal Medicine ◽  
Median Overall Survival ◽  
Gamma Knife Radiosurgery ◽  
Therapeutic Strategies ◽  
Chinese Herbal ◽  
Baseline Characteristics ◽  
Arterial Chemoembolization

Background. The potential advantages of Jiedu granule (a compound Chinese herbal medicine) combined therapeutic strategies compared with non-Jiedu granule therapeutic strategies for hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) remain unclear. Thus, the purpose of the study was to investigate the safety and efficacy of Jiedu granule for HCC with PVTT. Methods. We retrospectively reviewed the clinical data of 190 patients (94 for non-Jiedu and 96 for Jiedu) with HCC and PVTT from March 2012 to October 2016. Patients were followed up by outpatient examination and telephone till November 2018. Results. It was statistically insignificant between the two groups in baseline characteristics. Procedure-related adverse events (AEs) were observed and compared and most of them were not serious which were easily controlled or subsided naturally. No AE-induced death happened. The median overall survival (OS) rates in the single TACE plus GKR and Jiedu granule combined group were 11.3 months (95% CI: 9.168-13.435) and 15.8 months (95% CI: 13.244-18.339), respectively (p = 0.00047). Conclusions. Jiedu granule combined with TACE plus GKR is safe in HCC patients with PVTT and this Chinese herbal medicine is worthy to be promoted because of better prognosis which needs further research.

Sign in / Sign up

Export Citation Format

Share Document